Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector

Maria Dahl, Emma Smith, Sarah Warsi, Michael Rothe, Maria J. Ferraz, Johannes M. F. G. Aerts, Azadeh Golipour, Claudia Harper, Richard W. Pfeifer, Daniella Pizzurro,

Molecular Therapy — Methods & Clinical Development · 2020 · 23 citations · 27 references

DOIFull text

Open access

Concepts

Abstract

), are the underlying cause for the disorder, resulting in insufficient activity of the enzyme glucocerebrosidase, which in turn leads to a progressive accumulation of the lipid component glucocerebroside. In this study, we treat mice with signs consistent with GD1, with hematopoietic stem/progenitor cells transduced with a lentiviral vector containing an RNA transcript that, after reverse transcription, results in codon-optimized cDNA that, upon its integration into the genome encodes for functional human glucocerebrosidase. Five months after gene transfer, a highly significant reduction in glucocerebroside accumulation with subsequent reversal of hepatosplenomegaly, restoration of blood parameters, and a tendency of increased bone mass and density was evident in vector-treated mice compared to non-treated controls. Furthermore, histopathology revealed a prominent reduction of Gaucher cell infiltration after gene therapy. The vector displayed an oligoclonal distribution pattern but with no sign of vector-induced clonal dominance and a typical lentiviral vector integration profile. Cumulatively, our findings support the initiation of the first clinical trial for GD1 using the lentiviral vector described here.

References

27